UNSPSC 51422358: Paramethasone acetate

This classification denotes a therapeutic glucocorticoid with the molecular formula C24H31FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8X50N88ZDP, chemically known as 6alpha-fluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 21-acetate but more generally known as paramethasone acetate, which bears US NIH Compound Identifier 15333. European Medicines Agency schedules Paramethasone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03645MIG.

UNSPSC 51422358 Paramethasone acetate is a Commodity code for a synthetic corticosteroid pharmaceutical product. State and local procurement activity under this code shows minimal recent solicitation volume; the single identified opportunity from the source records concerns naloxone and drug deactivation systems procurement rather than paramethasone acetate, indicating a potential mismatch between the code assignment and the actual goods being acquired. When paramethasone acetate is procured by state and local bodies, it typically supports public health programs, correctional facilities, or community health agencies as part of broader pharmaceutical supply contracts. Issuing bodies soliciting pharmaceutical products at the commodity level tend to be county health departments, state health agencies, and local public health authorities rather than cities or school districts, though cooperative purchasing arrangements may expand the issuer base.

Seminole County, Florida posted an IFB (60459723LAS) in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023. This procurement does not directly align with the paramethasone acetate code classification. The source provides no additional recent opportunities under the paramethasone acetate code itself, no geographic concentration data, and no information about issuing-body patterns specific to this pharmaceutical commodity. The code appears to see limited recent state and local activity; business development professionals evaluating this commodity should monitor for health department and public health authority solicitations in states with active Medicaid programs or substantial correctional healthcare contracting.